Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ELI LILLY & CoLLY · Entity 2794 | EVP,Pres LLY Oncology&HdCorpBD | February 09, 2026 | February 11, 2026 |
| Loxo Oncology, Inc.LOXO · Entity 160155 | Chief Operating Officer | February 15, 2019 | February 15, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ELI LILLY & Co
Report date February 09, 2026 · Filed February 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 26,626.498 |
Reported balance
After 2026-02-09 transaction · row 1
1 source rowRow 1 · 2026-02-09 · Grant · Acquired 4,865.888 · Balance 26,626.498 |
| Common StockSEC Table I · non-derivative | IndirectVan Naarden Family Trust | 4,342 |
Reported balance
Holding disclosure · report date 2026-02-09 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 4,342 F1: The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy SLAT | 5,302 |
Reported balance
Holding disclosure · report date 2026-02-09 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 5,302 F2: On February 5, 2026, the Reporting Person's spouse transferred 5,302 shares of Eli Lilly and Company common stock to a spousal lifetime access trust, of which the Reporting Person is the trustee and a beneficiary. The transfer included 1,000 spouse-held shares previously reported as directly held due to an administrative error. F1: The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
F2: On February 5, 2026, the Reporting Person's spouse transferred 5,302 shares of Eli Lilly and Company common stock to a spousal lifetime access trust, of which the Reporting Person is the trustee and a beneficiary. The transfer included 1,000 spouse-held shares previously reported as directly held due to an administrative error.
Loxo Oncology, Inc.
Report date February 15, 2019 · Filed February 15, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-02-15 transaction · row 1
1 source rowRow 1 · 2019-02-15 · Disposition to issuer · Disposed 19,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.65 · Expires 2024-06-18 | Direct | 0 |
Reported balance
After 2019-02-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-02-15 · Disposition to issuer · Disposed 35,026 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.67 · Expires 2024-12-18 | Direct | 0 |
Reported balance
After 2019-02-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-02-15 · Disposition to issuer · Disposed 78,943 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.69 · Expires 2025-12-15 | Direct | 0 |
Reported balance
After 2019-02-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-02-15 · Disposition to issuer · Disposed 43,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.27 · Expires 2026-12-05 | Direct | 0 |
Reported balance
After 2019-02-15 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-02-15 · Disposition to issuer · Disposed 74,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.56 · Expires 2027-03-14 | Direct | 0 |
Reported balance
After 2019-02-15 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-02-15 · Disposition to issuer · Disposed 35,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $84.88 · Expires 2028-01-03 | Direct | 0 |
Reported balance
After 2019-02-15 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-02-15 · Disposition to issuer · Disposed 200,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $139.77 · Expires 2029-01-01 | Direct | 0 |
Reported balance
After 2019-02-15 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-02-15 · Disposition to issuer · Disposed 57,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.
F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 09, 2026 Filed Feb 11, 2026 21:25 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 4,865.888 | $1,044.67 | $5,083,247.22 |
DisclosureSEC source: 0001661254-26-000004 · wk-form4_1770845109.xml · nonDerivative · entry 1 Van Naarden Jacob · CIK 0001661254 · EVP,Pres LLY Oncology&HdCorpBD 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,626.498 Read SEC document |
| February 01, 2026 Filed Feb 3, 2026 21:31 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionRestricted Stock Unit · Derivative | 4,108 | $0.00 | $0.00 |
DisclosureSEC source: 0001661254-26-000002 · wk-form4_1770154258.xml · derivative · entry 5 Van Naarden Jacob · CIK 0001661254 · EVP,Pres LLY Oncology&HdCorpBD 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,108 shares Expires 2026-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2026 Filed Feb 3, 2026 21:31 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 1,909.375 | $1,037.15 | $1,980,308.28 |
DisclosureSEC source: 0001661254-26-000002 · wk-form4_1770154258.xml · nonDerivative · entry 2 Van Naarden Jacob · CIK 0001661254 · EVP,Pres LLY Oncology&HdCorpBD 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,760.61 Read SEC document |
| February 01, 2026 Filed Feb 3, 2026 21:31 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 4,108 | $0.00 | $0.00 |
DisclosureSEC source: 0001661254-26-000002 · wk-form4_1770154258.xml · nonDerivative · entry 1 Van Naarden Jacob · CIK 0001661254 · EVP,Pres LLY Oncology&HdCorpBD 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,669.985 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 13, 2025 Filed Aug 13, 2025 20:15 UTC | ELI LILLY & Co LLY · Entity 2794 | PurchaseCommon Stock | 1,000 | $647.36 | $647,360.00 |
DisclosureSEC source: 0000059478-25-000218 · wk-form4_1755116139.xml · nonDerivative · entry 1 Van Naarden Jacob · CIK 0001661254 · EVP & Pres., Lilly Oncology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,561.985 Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 21:28 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantRestricted Stock Unit · Derivative | 4,108 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-25-000057 · wk-form4_1739395681.xml · derivative · entry 4 Van Naarden Jacob · CIK 0001661254 · EVP & Pres., Lilly Oncology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,108 Underlying: Common Stock · 4,108 shares Expires 2026-02-01 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 21:28 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 6,103.824 | $868.88 | $5,303,490.60 |
DisclosureSEC source: 0000059478-25-000057 · wk-form4_1739395681.xml · nonDerivative · entry 1 Van Naarden Jacob · CIK 0001661254 · EVP & Pres., Lilly Oncology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,561.985 Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 21:26 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionRestricted Stock Unit · Derivative | 3,023 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-25-000030 · wk-form4_1738704376.xml · derivative · entry 5 Van Naarden Jacob · CIK 0001661254 · EVP & Pres., Lilly Oncology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,023 shares Expires 2025-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 21:26 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 1,409.839 | $811.08 | $1,143,492.22 |
DisclosureSEC source: 0000059478-25-000030 · wk-form4_1738704376.xml · nonDerivative · entry 2 Van Naarden Jacob · CIK 0001661254 · EVP & Pres., Lilly Oncology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,458.161 Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 21:26 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 3,023 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-25-000030 · wk-form4_1738704376.xml · nonDerivative · entry 1 Van Naarden Jacob · CIK 0001661254 · EVP & Pres., Lilly Oncology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,868 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 31, 2024 Filed Nov 1, 2024 20:17 UTC | ELI LILLY & Co LLY · Entity 2794 | GiftCommon Stock | 4,302 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-24-000247 · wk-form4_1730492255.xml · nonDerivative · entry 1 Van Naarden Jacob · CIK 0001661254 · EVP & Pres., Lilly Oncology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,845 F1 · shares: The reporting person transferred 4,302 shares of Eli Lilly and Company common stock to the reporting person's spouse. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:41 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantRestricted Stock Unit · Derivative | 3,023 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-24-000058 · wk-form4_1707946860.xml · derivative · entry 3 Van Naarden Jacob · CIK 0001661254 · EVP & Pres., Loxo@Lilly 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,023 Underlying: Common Stock · 3,023 shares Expires 2025-02-01 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:41 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 2,369 | $737.26 | $1,746,568.94 |
DisclosureSEC source: 0000059478-24-000058 · wk-form4_1707946860.xml · nonDerivative · entry 1 Van Naarden Jacob · CIK 0001661254 · EVP & Pres., Loxo@Lilly 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,147 Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 21:22 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionRestricted Stock Unit · Derivative | 3,618 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-24-000015 · wk-form4_1706908964.xml · derivative · entry 4 Van Naarden Jacob · CIK 0001661254 · EVP & Pres., Loxo@Lilly 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,618 shares Expires 2024-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 21:22 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 1,685 | $645.61 | $1,087,852.85 |
DisclosureSEC source: 0000059478-24-000015 · wk-form4_1706908964.xml · nonDerivative · entry 2 Van Naarden Jacob · CIK 0001661254 · EVP & Pres., Loxo@Lilly 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,778 Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 21:22 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 3,618 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-24-000015 · wk-form4_1706908964.xml · nonDerivative · entry 1 Van Naarden Jacob · CIK 0001661254 · EVP & Pres., Loxo@Lilly 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,463 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 21:35 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionRestricted Stock Unit · Derivative | 2,785 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-23-000079 · wf-form4_167701530938901.xml · derivative · entry 4 Van Naarden Jacob · CIK 0001661254 · EVP and CEO Loxo@Lilly 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,785 shares Expires 2023-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 21:35 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 1,314 | $335.01 | $440,203.14 |
DisclosureSEC source: 0000059478-23-000079 · wf-form4_167701530938901.xml · nonDerivative · entry 2 Van Naarden Jacob · CIK 0001661254 · EVP and CEO Loxo@Lilly 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,845 Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 21:35 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 2,785 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-23-000079 · wf-form4_167701530938901.xml · nonDerivative · entry 1 Van Naarden Jacob · CIK 0001661254 · EVP and CEO Loxo@Lilly 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,159 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 22:07 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 2,407 | $345.12 | $830,703.84 |
DisclosureSEC source: 0000059478-23-000065 · wf-form4_167641243711205.xml · nonDerivative · entry 1 Van Naarden Jacob · CIK 0001661254 · EVP and CEO Loxo@Lilly 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,374 Read SEC document |
| February 16, 2022 Filed Feb 17, 2022 21:44 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionRestricted Stock Unit · Derivative | 5,461 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-22-000065 · wf-form4_164513426243246.xml · derivative · entry 4 Van Naarden Jacob · CIK 0001661254 · SVP, CEO LoxoONC, Pres LlyONC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,461 shares Expires 2022-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 16, 2022 Filed Feb 17, 2022 21:44 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 2,186 | $243.84 | $533,034.24 |
DisclosureSEC source: 0000059478-22-000065 · wf-form4_164513426243246.xml · nonDerivative · entry 2 Van Naarden Jacob · CIK 0001661254 · SVP, CEO LoxoONC, Pres LlyONC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,967 Read SEC document |
| February 16, 2022 Filed Feb 17, 2022 21:44 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 5,461 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-22-000065 · wf-form4_164513426243246.xml · nonDerivative · entry 1 Van Naarden Jacob · CIK 0001661254 · SVP, CEO LoxoONC, Pres LlyONC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,153 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 28, 2021 Filed Dec 30, 2021 21:09 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantRestricted Stock Unit · Derivative | 3,618 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-21-000248 · wf-form4_164089857090230.xml · derivative · entry 1 Van Naarden Jacob · CIK 0001661254 · SVP, CEO LoxoONC, Pres LlyONC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,618 Underlying: Common Stock · 3,618 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. F2 · derivative.exercise_date: The restricted stock units vest on February 1, 2024. F2 · derivative.expiration_date: The restricted stock units vest on February 1, 2024. Read SEC document |
| February 15, 2019 Filed Feb 15, 2019 09:18 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 57,000 | $235.00 Strike: $139.77 | $13,395,000.00 |
DisclosureSEC source: 0001567619-19-004576 · doc1.xml · derivative · entry 8 Van Naarden Jacob · CIK 0001661254 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 57,000 shares Expires 2029-01-01 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. Read SEC document |
| February 15, 2019 Filed Feb 15, 2019 09:18 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 200,000 | $235.00 Strike: $84.88 | $47,000,000.00 |
DisclosureSEC source: 0001567619-19-004576 · doc1.xml · derivative · entry 7 Van Naarden Jacob · CIK 0001661254 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires 2028-01-03 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. Read SEC document |
| February 15, 2019 Filed Feb 15, 2019 09:18 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 35,000 | $235.00 Strike: $43.56 | $8,225,000.00 |
DisclosureSEC source: 0001567619-19-004576 · doc1.xml · derivative · entry 6 Van Naarden Jacob · CIK 0001661254 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,000 shares Expires 2027-03-14 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. Read SEC document |
| February 15, 2019 Filed Feb 15, 2019 09:18 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 74,000 | $235.00 Strike: $26.27 | $17,390,000.00 |
DisclosureSEC source: 0001567619-19-004576 · doc1.xml · derivative · entry 5 Van Naarden Jacob · CIK 0001661254 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 74,000 shares Expires 2026-12-05 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. Read SEC document |
| February 15, 2019 Filed Feb 15, 2019 09:18 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 43,000 | $235.00 Strike: $31.69 | $10,105,000.00 |
DisclosureSEC source: 0001567619-19-004576 · doc1.xml · derivative · entry 4 Van Naarden Jacob · CIK 0001661254 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 43,000 shares Expires 2025-12-15 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. Read SEC document |
| February 15, 2019 Filed Feb 15, 2019 09:18 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 78,943 | $235.00 Strike: $13.67 | $18,551,605.00 |
DisclosureSEC source: 0001567619-19-004576 · doc1.xml · derivative · entry 3 Van Naarden Jacob · CIK 0001661254 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 78,943 shares Expires 2024-12-18 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. Read SEC document |
| February 15, 2019 Filed Feb 15, 2019 09:18 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 35,026 | $235.00 Strike: $3.65 | $8,231,110.00 |
DisclosureSEC source: 0001567619-19-004576 · doc1.xml · derivative · entry 2 Van Naarden Jacob · CIK 0001661254 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,026 shares Expires 2024-06-18 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. Read SEC document |
| February 15, 2019 Filed Feb 15, 2019 09:18 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Disposition to issuerCommon Stock | 19,000 | $235.00 | $4,465,000.00 |
DisclosureSEC source: 0001567619-19-004576 · doc1.xml · nonDerivative · entry 1 Van Naarden Jacob · CIK 0001661254 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. Read SEC document |
| January 02, 2019 Filed Jan 2, 2019 17:04 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | GrantEmployee Stock Option (Right to Buy) · Derivative | 57,000 | $0.00 Strike: $139.77 | $0.00 |
DisclosureSEC source: 0001567619-19-000102 · doc1.xml · derivative · entry 1 Van Naarden Jacob · CIK 0001661254 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,000 Underlying: Common Stock · 57,000 shares Expires 2029-01-01 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 1/48th of the total number of shares on February 2, 2019, then an additional 1/48th vests on each monthly anniversary thereafter,until such time as the option is 100% vested, subject to the reporting person's continued service through each vesting date. Read SEC document |
| December 11, 2018 Filed Dec 12, 2018 17:17 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 7,000 | $0.00 Strike: $3.65 | $0.00 |
DisclosureSEC source: 0001567619-18-007788 · doc1.xml · derivative · entry 19 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,326 Underlying: Common Stock · 7,000 shares Expires 2024-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F16 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the shares subject to the option on May 12, 2015, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| December 11, 2018 Filed Dec 12, 2018 17:17 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 4,500 | $0.00 Strike: $13.67 | $0.00 |
DisclosureSEC source: 0001567619-18-007788 · doc1.xml · derivative · entry 18 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,943 Underlying: Common Stock · 4,500 shares Expires 2024-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F15 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning on January 19, 2015, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| December 11, 2018 Filed Dec 12, 2018 17:17 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Exercise / conversionCommon Stock | 7,000 | $3.65 | $25,536.00 |
DisclosureSEC source: 0001567619-18-007788 · doc1.xml · nonDerivative · entry 16 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 11, 2018 Filed Dec 12, 2018 17:17 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 541 | $140.16 | $75,826.56 |
DisclosureSEC source: 0001567619-18-007788 · doc1.xml · nonDerivative · entry 15 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,700 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F14 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $139.75 to $140.54 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 11, 2018 Filed Dec 12, 2018 17:17 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 500 | $139.23 | $69,615.00 |
DisclosureSEC source: 0001567619-18-007788 · doc1.xml · nonDerivative · entry 14 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,241 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F13 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $138.64 to $139.60 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 11, 2018 Filed Dec 12, 2018 17:17 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 500 | $137.73 | $68,865.00 |
DisclosureSEC source: 0001567619-18-007788 · doc1.xml · nonDerivative · entry 13 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,741 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F12 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $137.49 to $137.93 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 11, 2018 Filed Dec 12, 2018 17:17 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 1,759 | $137.09 | $241,141.31 |
DisclosureSEC source: 0001567619-18-007788 · doc1.xml · nonDerivative · entry 12 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,241 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F11 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $136.45 to $137.43 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 11, 2018 Filed Dec 12, 2018 17:17 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 800 | $135.92 | $108,736.00 |
DisclosureSEC source: 0001567619-18-007788 · doc1.xml · nonDerivative · entry 11 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F10 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.44 to $136.42 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 11, 2018 Filed Dec 12, 2018 17:17 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 400 | $134.74 | $53,896.00 |
DisclosureSEC source: 0001567619-18-007788 · doc1.xml · nonDerivative · entry 10 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,800 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F9 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $134.39 to $135.33 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 11, 2018 Filed Dec 12, 2018 17:17 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Exercise / conversionCommon Stock | 4,500 | $13.67 | $61,515.00 |
DisclosureSEC source: 0001567619-18-007788 · doc1.xml · nonDerivative · entry 9 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:17 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 4,500 | $0.00 Strike: $13.67 | $0.00 |
DisclosureSEC source: 0001567619-18-007788 · doc1.xml · derivative · entry 17 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,443 Underlying: Common Stock · 4,500 shares Expires 2024-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F15 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning on January 19, 2015, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:17 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 100 | $137.39 | $13,739.00 |
DisclosureSEC source: 0001567619-18-007788 · doc1.xml · nonDerivative · entry 8 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,700 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:17 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 200 | $136.48 | $27,296.00 |
DisclosureSEC source: 0001567619-18-007788 · doc1.xml · nonDerivative · entry 7 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,800 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F8 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $136.09 to $136.86 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:17 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 500 | $135.14 | $67,570.00 |
DisclosureSEC source: 0001567619-18-007788 · doc1.xml · nonDerivative · entry 6 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F7 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.06 to $135.21 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:17 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 1,400 | $134.65 | $188,510.00 |
DisclosureSEC source: 0001567619-18-007788 · doc1.xml · nonDerivative · entry 5 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,500 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F6 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $134.06 to $134.96 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:17 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 900 | $133.17 | $119,853.00 |
DisclosureSEC source: 0001567619-18-007788 · doc1.xml · nonDerivative · entry 4 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,900 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $132.66 to $133.54 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 17:17 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 1,000 | $132.23 | $132,230.00 |
DisclosureSEC source: 0001567619-18-007788 · doc1.xml · nonDerivative · entry 3 Van Naarden Jacob · CIK 0001661254 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,800 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $131.63 to $132.39 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.